Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
|Articles|August 14, 2020
Assembly Machine for Pen Injectors Offers Flexibility
Author(s)Pharmaceutical Technology Editors
The Optima FPA assembles pen injectors either fully or semi-automatically.
The Optima FPA assembles the components of pen injectors either fully or semi-automatically. The compact machine platform can be customized for pen systems made by different manufacturers.
Components can be either glued or clicked in place without having to change formats. The machine can also prime the injection device so the patient does not have to prime manually.
A new option for the machine is the ability to add a printer combined with 360° labeling. Customer-specific labels can be printed and positioned individually, then checked using a camera system.
Source:
Related to this article
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.